Dr Giedrius Gasiūnas, CEO and Co-Founder of Caszyme, describes the company’s research into engineered CRISPR-Cas12l nuclease Asp2Cas12l M82, a potential new tool for genome editing and the development of gene therapies. CRISPR has become one of the most widely used tools for gene editing across research and therapeutic development, but… Read More
CasZyme and Cirena have signed an agreement to collaborate on optimising the editing efficiency of CasZyme’s Cas12l CRISPR nuclease in human-relevant applications using Cirena’s synthetic 150-170nt guide RNAs. If successful, the work could improve editing efficiency of any resultant T-cell therapies (like CAR-T treatments), as well as other modalities relying… Read More
A new study has presented an innovative electromagnetic field (EMF)-responsive gene switch that enables fully reversible, safe, and precise control over gene expression. “Gene switches” hold significant potential for understanding gene expression and for therapeutic applications, particularly for the non-invasive treatment or management of genetic disorders. … Read More
CRISPR Therapeutics has shared positive Phase I data from an ongoing clinical trial evaluating CTX310, an investigational, in vivo CRISPR/Cas9 gene-editing therapy targeting ANGPTL3. A single-course treatment with CTX310 produced dose-dependent, durable reductions in circulating ANGPTL3 with a mean reduction from baseline of -73% (maximum… Read More
This is the latest episode of the free DDW narrated podcast, titled “Innovation enabled by new drug discovery technologies”, which covers two articles written for DDW Volume 24 – Issue 3, Summer 2023. They are called: “CRISPR breakthroughs: New solutions for common diseases” and “Re-assessing the risks of… Read More
Scientists have demonstrated that glioblastoma (GBM) tumour stem cells became less able to proliferate and invade tissues when the production of the prion protein was blocked, highlighting a potential new therapeutic target. GBM, which accounts for nearly half (49%) of all brain tumours, has an extremely low… Read More
The European Patent Office (EPO) has granted a new CRISPR/Cas9 patent (EP 4 289 948) to Professor Charpentier, along with The Regents of the University of California and the University of Vienna (collectively known as CVC). The divisional patent includes broad independent claims covering single guide RNAs, modified DNA-targeting RNAs… Read More
Researchers have uncovered that a molecule used to increase the efficiency of CRISPR-Cas9 gene editing destroys parts of the genome. The team discovered that while AZD 7648 does improve efficiency, it has the unwanted side effect of destroying other areas of the genome. They argue that alternatives… Read More
ERS Genomics and not-for-profit Medicines Discovery Catapult (MDC) have signed a non-exclusive commercial-use CRISPR license agreement. The partnership hopes to combine ERS’s CRISPR/Cas9 patent portfolio with MDC’s expertise and technology. As part of the deal, MDC and its partners will benefit from access to ERS’ CRISPR/Cas9 portfolio – the foundational… Read More
Lithuanian CRISPR gene editing company Caszyme has added early-stage mRNA synthesis, analysis, and optimisation to its range of offerings. The strategic development was announced at BIO2024 in San Diego, US. Caszyme CEO Dr Monika Paulė comments: “The demand for tailored gene editing solutions continues… Read More
Researchers from Japan have used CRISPR gene editing to enhance the effectiveness of rejuvenated cytotoxic T lymphocytes (rejTs) for targeted immunotherapy. RejTs constitute a promising approach for treating cervical cancer, though rejection by the host’s immune system is a major hurdle. In a recent… Read More
Following the first regulatory approval of a CRISPR-based drug in late 2023, over ten years since the CRISPR-Cas9 system was elucidated, there is considerable optimism about the future potential for gene editing technologies. The astonishing pace of innovation has led to new, potentially safer CRISPR-based techniques, including… Read More
This eBook explores the latest innovations in gene editing and CRISPR, the possibilities of new editing techniques and where the greatest potential for the technology might lie in the future. Download this exclusive eBook to learn more about: How CRISPR is providing new solutions for common diseases; The potential of base editing… Read More
ERS Genomics, a CRISPR/Cas9 licensing company, and StemSight, a biotechnology company developing stem cell based therapies for corneal blindness, have entered a non-exclusive CRISPR/Cas9 license agreement. The agreement grants StemSight access to ERS’ CRISPR/Cas9 patent portfolio. StemSight is a preclinical biotechnology company developing off-the-shelf cell therapies for… Read More
While attending Life Science Baltics 2023, Diana Spencer spoke to Monika Paule, CEO and Co-founder of Caszyme, about creating a company based on CRISPR gene editing and some of the challenges of operating in this dynamic area of research. DS: What was the motivation for launching Caszyme and what challenges did… Read More
Listen to this article on the DDW Podcast: Rolf Turk, Senior Manager, Genomics Medicine at Integrated DNA Technologies, examines how CRISPR is being used to enhance cancer therapies. Since its discovery in 2012, CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) technology has revolutionised the biomedicine and cell and gene therapy fields,… Read More
